An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment
| Registry | NCT01033656, acronym NordicAOSD05 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional; randomized, parallel, masking: none, treatment |
| Enrollment | 23 (Actual) |
| Sponsor | University of Helsinki (Other); collaborators: Uppsala University Hospital, Helse Stavanger HF, Tampere University Hospital, Turku University Hospital, Oulu University Hospital, Kuopio University Hospital, Jyväskylä Central Hospital, Satakunta Central Hospital, University Hospital, Umeå, University Hospital, Linkoeping |
| Conditions | Adult-Onset Still's Disease |
| Interventions | anakinra, comparators (Drug) |
| Dates | start 2005-12-01, primary completion 2010-03-01, completion 2010-04-01, first posted 2009-12-16, last updated 2017-03-06 |
| Locations | 1 site in Sweden |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Adult-Onset Still's Disease All trials of anakinra All trials of comparators
An open, randomized, parallel-group, comparative, multicentre study. Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide, cyclosporin A or sulphasalazine. Patients enter the study if considered refractory to corticosteroids (prednisolone equivalent ≥10 mg/day) at the time of randomization.
The randomized phase of the study will be followed by an open-label extension (OLE) phase, to follow-up drug survival, efficacy, tolerability and disease-related parameters of long-term treatment with anakinra or one of the study DMARDs or a combination of study drugs for additional 28 weeks.
Product: Kineret (anakinra) Comparative agents: Methotrexate or azathioprine or leflunomide or cyclosporin A or sulphasalazine Protocol title: An open, randomized study treating refractory adult-onset Still's disease with IL-1ra anakinra (Kineret, compared to an established, single anti-rheumatic treatment Target Disease: Adult-onset Still's disease Patients: 23 patients diagnosed with AOSD, living in the four Nordic countries.
Study Objectives: To follow the changes in clinical status and disease activity in patients receiving anakinra, compared to those treated with an established DMARD, in addition to corticosteroids in patients with refractory AOSD. To compare the changes in disease-related parameters (global health, patient's assessment on disease, laboratory values) in the two randomized groups. To assess the safety of anakinra in AOSD. To follow-up drug survival, efficacy, tolerability and disease-related parameters of long-term treatment in AOSD (open phase).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Anakinra | Experimental | Drug: anakinra | experimental drug of study |
| comparator | Active comparator | Drug: comparators | comparators:methotrexate, azathioprine, leflunomide or supfasalazine |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Must be diagnosed with AOSD according to preliminary classification by Yamaguchi (1992). * Other diseases with similar symptoms must be excluded. Has been exposed to a corticosteroid for ≥2 months prior to randomization for AOSD. * Needs a prednisolone dose ≥10 mg/day or equivalent, yet unacceptable disease activity determined by the investigator. * Anti-TNF agents must be discontinued 4 to 8 weeks prior to commencing study medication. Exclusion Criteria: * Use of corticosteroids (prednisolone equivalent <10 mg/day. * History of recurrent or chronic infection, including: * tuberculosis * any malignancy * any other major chronic inflammatory disease syndrome * drug or alcohol abuse * known positivity for hepatitis B, C or HIV. * Use of anti-TNF agents during ≤4 weeks (etanercept) or≤8 weeks (infliximab or adalimumab) prior to randomization.
| Facility | City | Country | Status |
|---|---|---|---|
| Ann Kataja Knight | Uppsala | Sweden |
NIH grants: 2005